Entrada Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients through innovative medicines that target previously inaccessible intracellular sites. The company specializes in developing Endosomal Escape Vehicle (EEV™)-therapeutics, which facilitate the efficient delivery of RNA- and protein-based therapies for various conditions, including neuromuscular and ocular diseases. With a strong focus on collaboration and a commitment to patient care, Entrada is advancing a robust portfolio of clinical programs, including treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. The company values creativity, tenacity, and humanity, fostering a dynamic and supportive work environment for its team of experts.